Val-Cit-PAB-DEA-Dxd (TFA)
Val-Cit-PAB-DEA-Dxd (Compound 81) TFA is a Drug-Linker Conjugates for ADC, which is composed of a linker and a toxic molecule Dxd (HY-13631D) . Val-Cit-PAB-DEA-Dxd can be used for ADC synthesis[1].
Product Specifications
UNSPSC
12352005
Target
Drug-Linker Conjugates for ADC
Related Pathways
Antibody-drug Conjugate/ADC Related
Field of Research
Cancer
Purity
99.11
Solubility
DMSO : ≥ 100 mg/mL
Smiles
CN(C(OCC1=CC=C(NC([C@H](CCCNC(N)=O)NC([C@H](C(C)C)N)=O)=O)C=C1)=O)CCN(C)C(OCC(N[C@@H]2C3=C4C(C(N5C4)=CC([C@](O)(C(OC6)=O)CC)=C6C5=O)=NC7=CC(F)=C(C)C(CC2)=C73)=O)=O.OC(C(F)(F)F)=O
Molecular Formula
C52H62F4N10O14
Molecular Weight
1127.10
References & Citations
[1]Dechun Wu, et al. Pegylated antibody hydroxyl-bearing drug conjugate. Patent WO2023151679A1.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, sealed storage, away from moisture and light)
Scientific Category
ADC Related
Clinical Information
No Development Reported
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
